ClinicalTrials.Veeva

Menu

Role of Double Cuffed PTFE Arteriovenous Grafts in Enhancing Long-term Patency in Hemodialysis Patients (Extended Poly Tetra Fluoro Ethylene) (ePTFE)

M

Mansoura University

Status

Unknown

Conditions

End Stage Renal Disease

Treatments

Procedure: Double vein cuffed ePTFE graft both at the inflow and outflow ends
Procedure: single vein cuffed eTFE graft both at the inflow and outflow ends
Procedure: ePTFE graft without any cuff

Study type

Interventional

Funder types

Other

Identifiers

NCT03405233
R.18.01.6.R1

Details and patient eligibility

About

this randomized controlled trial will compare the double vein cuffed synthetic arteriovenous graft to the single vein cuffed synthetic and the non cuffed synthetic as regard to long-term patency of each modality

Full description

End-stage renal disease (ESRD) arises from many heterogeneous disease pathways that alter the function and structure of the kidney irreversibly, over months or years.End-stage renal disease (ESRD) arises from many heterogeneous disease pathways that alter the function and structure of the kidney irreversibly, over months or years. Haemodialysis (HD) is a lifeline therapy for patients with ESRD. A proportion of hemodialysis patients exhaust all options for permanent vascular access (fistula or graft) in both upper extremities.ePTFE grafts are easily subjected to graft outflow tract intimal hyperplasia, which may lead to graft outlet stenosis and graft thrombosis after a certain period of usage. The commonest cause of PTFE graft failure is intimal hyperplasia (IH) at the venous anastomoses. our study aims to evaluate the influence of double cuffed ePTFE grafts with autologous vein cuffs on the long-term patency of dialysis access, and compare the clinical patency and the complications occurring with the usage of the double cuffed graft to that with standard non cuffed grafts in chronic renal hemodialysis therapy.

this randomized controlled trial will compare the double vein cuffed synthetic arteriovenous graft to the single vein cuffed synthetic and the non cuffed synthetic as regard to long term patency of each modality

Enrollment

220 estimated patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Patients with end stage renal diseases and GFR less than 30
  2. By clinical examination in ability to palpate distal or proximal upper limb veins 3. By duplex examination the diameter of cephalic or basilic veins are less than 3 mm or reported to be incompressible 4. Patients with previous history of failed attempts of autogenous vein creation 5. Patients with border line cephalic or basilica vein (3mm) and on intraoperative the vein diameter appears to be unsuitable (less than 3 mm).

Exclusion criteria

  1. All patients with palpable suitable forearm or arm veins
  2. Patients with baseline blood pressure less than 110/70
  3. Brachial artery of diameter less than 4 mm
  4. Patients with ligated brachial artery
  5. Patients with history of central vein stenosis
  6. Patients with immunodeficiency states

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

220 participants in 3 patient groups

Group A
Experimental group
Description:
Double vein cuff PTFE graft both at the inflow and outflow ends
Treatment:
Procedure: Double vein cuffed ePTFE graft both at the inflow and outflow ends
Group B
Active Comparator group
Description:
Single vein cuffed PTFE graft at the outflow end
Treatment:
Procedure: single vein cuffed eTFE graft both at the inflow and outflow ends
Group C
Active Comparator group
Description:
PTFE graft without vein cuff will be used
Treatment:
Procedure: ePTFE graft without any cuff

Trial contacts and locations

1

Loading...

Central trial contact

Hussein mohamed Abdelaziz, PHD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems